Purdue Pharma Names Jean-Jacques Charhon Chief Financial Officer

STAMFORD, Conn., June 1, 2015 /PRNewswire/ -- Purdue Pharma, a leading specialty pharmaceutical company, today announced that Jean-Jacques "JJ" Charhon has joined the company as Executive Vice President and Chief Financial Officer, responsible for Purdue's financial, procurement, and information technology functions.

Purdue Pharma, L.P. logo.
"JJ is a proven leader with experience in the pharmaceutical, healthcare, and technology industries," said Purdue President & CEO Mark Timney. "His expertise and proven record of success leading finance organizations will be a valuable asset to Purdue's growth strategy."

JJ joins Purdue from Cnova, one of the largest global eCommerce companies, where he served as Executive Vice President and Chief Financial Officer, with responsibility for investor relations, planning, and external reporting.

Prior to joining Cnova, JJ worked for four years for Hewlett Packard, where he joined as Chief Financial Officer of the PC division before becoming Chief Operating Officer of Enterprise Services, a $23 billion division of HP. This role followed eight years at General Electric and four years at Novartis, where he held various Global Financial Leadership roles of increasing responsibility. His last role at Novartis was Global Head of Business Planning, Analysis & Investor Relations.

JJ earned his Baccalaureate in Math, Physics & Chemistry at the French Lycee of Brussels, and holds a Master in Business Administration from the Universite Libre de Bruxelles Solvay School of Management.

Further Additions to Purdue's Finance Organization
Thomas Leggett joins Purdue as Treasurer and Head of Business Development Finance with responsibility for business development opportunity evaluations, capital markets activities, and management of treasury and insurance operations.

Tom joins the company with a broad range of investment banking experience and was most recently an Executive Director and one of three senior calling officers leading the biopharmaceutical investment banking coverage effort in the Americas at UBS Securities LLC. Prior to UBS, he worked in healthcare investment banking at Lazard Freres & Company and J.P. Morgan Securities Inc. Tom holds a Master's in Business Administration from The Wharton School and a Bachelor of Arts Degree in Economics from Columbia University.

Dan Russo joins the company as Tax Officer with responsibility for all tax matters, including business development tax structuring. Dan most recently was Vice President Tax, Americas for Diageo; Tax Director for ITT Corporation; and Tax Counsel at Xerox Corporation. Dan holds a Bachelor of Arts Degree in Accounting from Rutgers University, a JD from Boston College Law School, and an LLM in Taxation from Boston University Law School.

Edward Mahony is assuming the role of Executive Vice President for Due Diligence & Integration Management, with responsibility for optimizing the value of potential and completed business development transactions. He began his career at Purdue in 1993 as Vice President and Chief Financial Officer, and was promoted to Executive Vice President and Chief Financial Officer in 1999.

About Purdue Pharma
Purdue Pharma and its associated U.S. companies are privately-held pharmaceutical companies known for pioneering research on chronic pain. Headquartered in Stamford, CT, Purdue is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products. Additional information about Purdue can be found at www.purduepharma.com.

Logo - http://photos.prnewswire.com/prnh/20100921/NY67262

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/purdue-pharma-names-jean-jacques-charhon-chief-financial-officer-300091567.html

SOURCE Purdue Pharma

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.